glp-1 news Science's 2023 Breakthrough: Agonists Show Promise Against Obesity-Associated Disease GLP-1 demand surges. Here's how

They reduce hemoglobin A 1c (HbA 1c ), weight, major cardiovascular events, and renal decline

Shaobo Ding, [email protected] These authors have contributed equally to this work This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

The findings suggest semaglutide could become an important tool for clinicians treating both CKD and type 2 diabetes, according to Matthew Weir, MD, professor and chief of the division of nephrology at University of Maryland School of Medicine

For example, using a mouse model of Huntingtons disease, they found that exendin-4 reduces the accumulation of the mutant huntingtin protein, which is implicated in the diseases onset and progression